(Q34319478)

1 August 2017

1 reference

title

Pleiotropic effects of statins and their clinical significance (English)

1 reference

1 August 2017

1 reference

LaRosa JC

1

1 reference

PubMed ID

11472710

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

American Journal of Cardiology

1 August 2017

1 reference

1 August 2017

88

1 reference

1 August 2017

3

1 reference

1 August 2017

291-293

1 reference

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Lipids and the endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Low-density lipoprotein-independent effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Effect of pravastatin on outcomes after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Direct vascular effects of HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Influences of lipid-modifying agents on hemostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Cholesterol, stroke risk, and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Women, dyslipoproteinemia, and estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901643-5

10.1016/S0002-9149(01)01643-5

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11472710